viewShield Therapeutics PLC

Shield Therapeutics to take kidney disease treatment forward to phase III study

Hyperphosphatemia is a condition where due to renal failure there is too much phosphorus present in the blood

Shield Therapeutics PLC -

Shield Therapeutics PLC (LON:STX) has published a paper highlighting a study into the benefits of PT20 as a treatment for people with the kidney disease hyperphosphatemia.

Published recently in Nephrology Dialysis Transplantation, the paper detailed the results of a phase IIb study for PT20, an iron-based phosphate binder.

Hyperphosphatemia is a condition where due to renal failure there is too much phosphorus present in the blood.

Read the paper here

Shield said that the study demonstrated that PT20 treatment for 28 days resulted in a statistically significant and dose-dependent reduction in serum phosphate concentration and was generally well tolerated.

The study, which was funded by Shield, was a pivotal study to support marketing authorisation submissions, it added.

Shield said it has agreed with the US FDA that PT20 requires only one further pivotal Phase III study after which regulatory filings for marketing approval would be expected to follow.

This will involve the development of a new formulation of PT20, which will allow the Phase III study to be carried out and which will be suitable for commercial use.

Formulation work could start in the second half of 2020, Shield added, which would potentially allow the Phase III study to start in 2022, subject to finance being available. 


Quick facts: Shield Therapeutics PLC

Price: 117 GBX

Market: LSE
Market Cap: £137.11 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...



Shield's Feraccru likely to command 'high market share and branded pricing'

Capital Network analyst Emma Ulker assesses recent progress made at Shield Therapeutics PLC (LON:STX) with its lead asset Feraccru. The drug's approved and marketed in Europe, with a US approval decision pending for July 27. Feraccru is an oral product absorbed in the gut. It's also...

on 11/5/19

2 min read